Luisel Ricks-Santi1, J Tyson McDonald1, Bert Gold2, Michael Dean2, Nicole Thompson3, Muneer Abbas4, Bradford Wilson4, Yasmine Kanaan5, Tammey J Naab3, Georgia Dunston4,5. 1. Cancer Research Center, Hampton University, Hampton, Virginia. 2. Laboratory of Experimental Immunology, National Cancer Institute, Frederick, Maryland. 3. Howard University Cancer Center, Washington, DC. 4. National Human Genome Center, Howard University Department of Community and Family Medicine, Washington, DC. 5. Department of Microbiology, Howard University School of Medicine, Washington, DC.
Abstract
BACKGROUND: Variants of unknown significance (VUSs) have been identified in BRCA1 and BRCA2 and account for the majority of all identified sequence alterations. Notably, VUSs occur disproportionately in people of African descent hampering breast cancer (BCa) management and prevention efforts in the population. Our study sought to identify and characterize mutations associated with increased risk of BCa at young age. METHODS: In our study, the spectrum of mutations in BRCA1 and BRCA2 was enumerated in a cohort of 31 African American women of early age at onset breast cancer, with a family history of breast or cancer in general and/or with triple negative breast cancer. To improve the characterization of the BRCA1 and BRCA2 variants, bioinformatics tools were utilized to predict the potential function of each of the variants. RESULTS: Using next generation sequencing methods and in silico analysis of variants, a total of 197 BRCA1 and 266 BRCA2 variants comprising 77 unique variants were identified in 31 patients. Of the 77 unique variants, one (1.3%) was a pathogenic frameshift mutation (rs80359304; BRCA2 Met591Ile), 13 (16.9%) were possibly pathogenic, 34 (44.2%) were benign, and 29 (37.7%) were VUSs. Genetic epidemiological approaches were used to determine the association with variant, haplotype, and phenotypes, such as age at diagnosis, family history of cancer and family history of breast cancer. There were 5 BRCA1 SNPs associated with age at diagnosis; rs1799966 (P=.045; Log Additive model), rs16942 (P=.033; Log Additive model), rs1799949 (P=.058; Log Additive model), rs373413425 (P=.040 and .023; Dominant and Log Additive models, respectively) and rs3765640 (P=.033 Log Additive model). Additionally, a haplotype composed of all 5 SNPs was found to be significantly associated with younger age at diagnosis using linear regression modeling (P=.023). Specifically, the haplotype containing all the variant alleles was associated with older age at diagnosis (OR= 5.03 95% CI=.91-9.14). CONCLUSIONS: Knowing a patient's BRCA mutation status is important for prevention and treatment decision-making. Improving the characterization of mutations will lead to better management, treatment, and BCa prevention efforts in African Americans who are disproportionately affected with aggressive BCa and may inform future precision medicine genomic-based clinical studies.
BACKGROUND: Variants of unknown significance (VUSs) have been identified in BRCA1 and BRCA2 and account for the majority of all identified sequence alterations. Notably, VUSs occur disproportionately in people of African descent hampering breast cancer (BCa) management and prevention efforts in the population. Our study sought to identify and characterize mutations associated with increased risk of BCa at young age. METHODS: In our study, the spectrum of mutations in BRCA1 and BRCA2 was enumerated in a cohort of 31 African American women of early age at onset breast cancer, with a family history of breast or cancer in general and/or with triple negative breast cancer. To improve the characterization of the BRCA1 and BRCA2 variants, bioinformatics tools were utilized to predict the potential function of each of the variants. RESULTS: Using next generation sequencing methods and in silico analysis of variants, a total of 197 BRCA1 and 266 BRCA2 variants comprising 77 unique variants were identified in 31 patients. Of the 77 unique variants, one (1.3%) was a pathogenic frameshift mutation (rs80359304; BRCA2Met591Ile), 13 (16.9%) were possibly pathogenic, 34 (44.2%) were benign, and 29 (37.7%) were VUSs. Genetic epidemiological approaches were used to determine the association with variant, haplotype, and phenotypes, such as age at diagnosis, family history of cancer and family history of breast cancer. There were 5 BRCA1 SNPs associated with age at diagnosis; rs1799966 (P=.045; Log Additive model), rs16942 (P=.033; Log Additive model), rs1799949 (P=.058; Log Additive model), rs373413425 (P=.040 and .023; Dominant and Log Additive models, respectively) and rs3765640 (P=.033 Log Additive model). Additionally, a haplotype composed of all 5 SNPs was found to be significantly associated with younger age at diagnosis using linear regression modeling (P=.023). Specifically, the haplotype containing all the variant alleles was associated with older age at diagnosis (OR= 5.03 95% CI=.91-9.14). CONCLUSIONS: Knowing a patient's BRCA mutation status is important for prevention and treatment decision-making. Improving the characterization of mutations will lead to better management, treatment, and BCa prevention efforts in African Americans who are disproportionately affected with aggressive BCa and may inform future precision medicine genomic-based clinical studies.
Entities:
Keywords:
African American; BRCA1; BRCA2; Cancer Disparities; Familial Breast Cancer; Hereditary Breast Cancer; Next Generation Sequencing; Precision Medicine
Authors: C M Perou; S S Jeffrey; M van de Rijn; C A Rees; M B Eisen; D T Ross; A Pergamenschikov; C F Williams; S X Zhu; J C Lee; D Lashkari; D Shalon; P O Brown; D Botstein Journal: Proc Natl Acad Sci U S A Date: 1999-08-03 Impact factor: 11.205
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Olufunmilayo I Olopade; James D Fackenthal; Georgia Dunston; Michael A Tainsky; Francis Collins; Carolyn Whitfield-Broome Journal: Cancer Date: 2003-01-01 Impact factor: 6.860
Authors: S R Young; Robert T Pilarski; Talia Donenberg; Charles Shapiro; Lyn S Hammond; Judith Miller; Karen A Brooks; Stephanie Cohen; Beverly Tenenholz; Damini Desai; Inuk Zandvakili; Robert Royer; Song Li; Steven A Narod Journal: BMC Cancer Date: 2009-03-19 Impact factor: 4.430
Authors: Babatunde Adedokun; Yonglan Zheng; Paul Ndom; Antony Gakwaya; Timothy Makumbi; Alicia Y Zhou; Toshio F Yoshimatsu; Alex Rodriguez; Ravi K Madduri; Ian T Foster; Aminah Sallam; Olufunmilayo I Olopade; Dezheng Huo Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-12-23 Impact factor: 4.254
Authors: Parvathi A Myer; Jessica K Lee; Russell W Madison; Kith Pradhan; Justin Y Newberg; Carmen R Isasi; Samuel J Klempner; Garrett M Frampton; Jeffery S Ross; Jeffrey M Venstrom; Alexa B Schrock; Sudipto Das; Leonard Augenlicht; Amit Verma; John M Greally; Srilakshmi M Raj; Sanjay Goel; Siraj M Ali Journal: Cancer Discov Date: 2022-05-02 Impact factor: 38.272
Authors: Leann A Lovejoy; Seth K Rummel; Clesson E Turner; Craig D Shriver; Rachel E Ellsworth Journal: Fam Cancer Date: 2020-10-21 Impact factor: 2.375
Authors: Noura S Abul-Husn; Emily R Soper; Jacqueline A Odgis; Sinead Cullina; Dean Bobo; Arden Moscati; Jessica E Rodriguez; Ruth J F Loos; Judy H Cho; Gillian M Belbin; Sabrina A Suckiel; Eimear E Kenny Journal: Genome Med Date: 2019-12-31 Impact factor: 11.117